Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women-effects on lipid metabolism during 12 r/lonths of treatment

International Journal of Fertility and Menopausal Studies

Volumn 41, Issue 5, 1996, Pages 476-483

  Andersson, Kerstin ^a   Stadberg, Elisabeth ^a   Mattsson, Lars Ake ^a   Rybo, Göran ^b   Samsioe, Göran ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Hormone replacement therapy; Levonorgestrel releasing intrauterine device; Lipids

Indexed keywords

ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORGESTREL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MIXTURE; DRUG RELEASE; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MENOPAUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; COHORT STUDIES; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; LIPID METABOLISM; LIPIDS; MIDDLE AGED; PREMENOPAUSE; PROGESTERONE CONGENERS;

EID: 0029844052     PISSN: 10693130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bush TL, Barrett-Connor E, Cowan LD, et al: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 6:1102-1109, 1987.
2. Stampfer MJ, Colditz GA, Willett WC, et al: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 325:756-762, 1991.
3. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265:1861-1867, 1991.
4. Sullivan JM, Vander Zwaag R, Lemp GF, et al: Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 108:358-363, 1988.
5. Barnes RB, Roy S, Lobo RA: Comparison of lipid and androgen levels after conjugated estrogen or depomedroxyprogesterone acetate treatment in postmenopausal women. Obstet Gynecol 66:216-219, 1985.
6. Whitehead MI, Townsend PT, Pryse-Davis J, et al: Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 305:1599-1605, 1981.
7. Henderson BE, Ross RK, Lobo RA, et al: Re-evaluating the role of progestin therapy after the menopause. Fertil Steril 49:S9-S15, 1988.
8. Andersson K, Mattsson L-Ä, Rybo G, et al: Intrauterine release of levonorgestrel-A new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 79:963-967, 1992.
9. Nilsson CG, Kostiainen E, Ehnholm C: Serum lipids and high density lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel. Int J Fertil 26:135-137, 1981.
10. Luukkainen T, Allonen H, Nielsen NC, et al: Five years' experience of intrauterine contraception with the Nova-T and Copper-T-200. Am J Obstet Gynecol 147:885-892, 1983.
11. Walton KW, Scott PJ, Dykes PW, Davies JWL: The significance of alterations in serum lipids in thyroid dysfunction. Alterations of the metabolism and turnover of 1.31-1-low density lipoproteins in hyperthyroidism and thyrotoxicosis. Clin Sei 29:217-238. 1965.
12. Langer T, Strobert W, Levy RI: The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J. Clin Invest 51:1528-1536, 1972.
13. Eisenberg S, Windmueller HG, Levy RI: Metabolie fate of rat and human lipoprotein apoproteins in the mt.JLipid Res 14:446-58, 1973.
14. Ottosson ÜB, Johansson BG, von Schoultz B: Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 151:746-750, 1985.
15. Tikkanen MJ, Esko A, Nikkilä T: Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 113:562-567. 1987.
16. Parish E, Hart DM, Gray CE, et al: Effects of treatment with oestradiol/levonorgestrel on bone, lipoproteins and hormone status in postmenopausal women. Clin Endocrinol 31:607-615, 1989.
17. Crook D, Cust M, Kevin F, et al: Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol 166:950-955, 1992.
18. Hirvonen E, Lipasti A, Mälkönen M, et al: Clinical and metabolic effects of unopposed estrogen and two estrogen-progestogen regimens in postmenopausal women. Maturitas 9:69-79, 1987.
19. Jensen J, Riis BJ, Strom V, et al: Continuous oestrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 94:130-135, 1987.
20. Sporrong T, Hellgren M, Samsioe G, et al: Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women. Obstet Gynecol 73:754-758, 1989.
21. Witzum J, Schonfeld G: High density lipoproteins. Diabetes 28:326-336, 1979.
22. Matthews KA, Meilahn E, Kuller LH, et al: Menopause and risk factors for coronary heart disease. N EnglJMed 321:641-646, 1989.
23. Lapidus L, Bengtsson C, Lindquist O, et al: Triglycérides main lipid risk factor for cardiovascular disease in women? Ac ta Med Scand 217:481-489, 1985.
24. Austin ME: Plasma triglycérides as a risk factor for coronary heart disease. The epidemiological evidence and beyond. Am J Epidemiol 129:249-259, 1989.
25. Glueck CJ, Ford S, Steiner P, et al: Triglycéride removal efficiency and lipoprotein lipases; effects of oxandrolone;Metabo7jsm 22:807-814, 1973.
26. Mattsson L-A, Cullberg G, Samsioe G: Evaluation of a continuous estrogen-progestogen regimen for climacteric complaints. Maturitas 4:95-102, 1982.